Tweet
Vaccines (Basel)
. 2022 Jun 3;10(6):897.
doi: 10.3390/vaccines10060897.
Chimeric Antigen by the Fusion of SARS-CoV-2 Receptor Binding Domain with the Extracellular Domain of Human CD154: A Promising Improved Vaccine Candidate
Ileanet Ávalos 1 , Thailin Lao 1 , Elsa María Rodríguez 1 , Yasser Zamora 1 , Alianet Rodríguez 1 , Ailyn Ramón 1 , Gilda Lemos 1 , Ania Cabrales 1 , Monica Bequet-Romero 1 , Dionne Casillas 1 , Ivan Andújar 1 , Luis Ariel Espinosa 1 , Luis Javier González 1 , Yanitza Alvarez 1 , Yamila Carpio 1 , Mario Pablo Estrada 1
Affiliations
- PMID: 35746505
- DOI: 10.3390/vaccines10060897
Abstract
COVID-19 is a respiratory viral disease caused by a new coronavirus called SARS-CoV-2. This disease has spread rapidly worldwide with a high rate of morbidity and mortality. The receptor-binding domain (RBD) of protein spike (S) mediates the attachment of the virus to the host's cellular receptor. The RBD domain constitutes a very attractive target for subunit vaccine development due to its ability to induce a neutralizing antibody response against the virus. With the aim of boosting the immunogenicity of RBD, it was fused to the extracellular domain of CD154, an immune system modulator molecule. To obtain the chimeric protein, stable transduction of HEK-293 was carried out with recombinant lentivirus and polyclonal populations and cell clones were obtained. RBD-CD was purified from culture supernatant and further characterized by several techniques. RBD-CD immunogenicity evaluated in mice and non-human primates (NHP) indicated that recombinant protein was able to induce a specific and high IgG response after two doses. NHP sera also neutralize SARS-CoV-2 infection of Vero E6 cells. RBD-CD could improve the current vaccines against COVID-19, based in the enhancement of the host humoral and cellular response. Further experiments are necessary to confirm the utility of RBD-CD as a prophylactic vaccine and/or booster purpose.
Keywords: HEK-293; RBD; SARS-CoV-2; lentivirus; vaccine.